Literature DB >> 31760542

Zoledronic acid in nine patients with transient osteoporosis of the hip.

Gerasimos Evangelatos1, George E Fragoulis2, Alexios Iliopoulos3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31760542     DOI： 10.1007/s10067-019-04840-7

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


× No keyword cloud information.
  10 in total

Review 1.  Transient osteoporosis of the hip: review of the literature.

Authors:  K Asadipooya; L Graves; L W Greene
Journal:  Osteoporos Int       Date:  2017-03-17       Impact factor: 4.507

Review 2.  Transient osteoporosis of the hip, complete resolution after treatment with alendronate as observed by MRI description of eight cases and review of the literature.

Authors:  Yasser Emad; Yasser Ragab; Nashwa El-Shaarawy; Johannes J Rasker
Journal:  Clin Rheumatol       Date:  2012-08-30       Impact factor: 2.980

3.  Zoledronic acid is effective and safe in migratory osteoporosis.

Authors:  Gerasimos Evangelatos; George E Fragoulis; Evangelia Zampeli; Maria Kechagia; Alexios Iliopoulos
Journal:  Rheumatology (Oxford)       Date:  2020-02-01       Impact factor: 7.580

4.  TRANSIENT OSTEOPOROSIS: CLINICAL SPECTRUM IN ADULTS AND ASSOCIATED RISK FACTORS.

Authors:  Anupam Kotwal; Maria Daniela Hurtado; Jad G Sfeir; Robert A Wermers
Journal:  Endocr Pract       Date:  2019-03-13       Impact factor: 3.443

5.  Risk factors in transient osteoporosis: a retrospective study on 23 cases.

Authors:  Carlo Trevisan; Raymond Klumpp; Riccardo Compagnoni
Journal:  Clin Rheumatol       Date:  2016-03-16       Impact factor: 2.980

6.  Zoledronic Acid Treatment in Primary Bone Marrow Edema Syndrome.

Authors:  Bryan Josué Flores-Robles; Jesus Sanz-Sanz; Adel Abel Sanabria-Sanchinel; Dixie Huntley-Pascual; José Luis Andréu Sánchez; José Campos Esteban; Ricardo Blanco; Carolina Merino-Argumanez; Maria Espinosa-Malpartida; Maria Consuleo Ramos-Giráldez; Hildegarde Godoy-Tundidor; Maria Mercedes Jiménez-Palop; Carmen Barbadillo Mateos; Luis Fernando Villa-Alcázar; Carlos Maria Isasi; Juan Bartolome Mulero
Journal:  J Pain Palliat Care Pharmacother       Date:  2017-02-17

7.  Intravenous pamidronate in the treatment of transient osteoporosis of the hip.

Authors:  M Varenna; F Zucchi; L Binelli; S Failoni; M Gallazzi; L Sinigaglia
Journal:  Bone       Date:  2002-07       Impact factor: 4.398

8.  Bone Marrow Edema Syndrome of the Foot and Ankle: Mid- to Long-Term Follow-up in 18 Patients.

Authors:  Dishan Singh; Andrea Ferrero; Barry Rose; Andrew Goldberg; Nicholas Cullen
Journal:  Foot Ankle Spec       Date:  2015-10-12

Review 9.  Primary bone marrow oedema syndromes.

Authors:  Sanjeev Patel
Journal:  Rheumatology (Oxford)       Date:  2013-09-29       Impact factor: 7.580

10.  Oral bisphosphonates in treatment of transient osteoporosis.

Authors:  L Kibbi; Z Touma; N Khoury; T Arayssi
Journal:  Clin Rheumatol       Date:  2007-10-16       Impact factor: 2.980
  10 in total
  2 in total

1.  Zoledronic acid is effective in the management of migratory osteoporosis unresponsive to conservative treatment and risedronate: A case report.

Authors:  Gerasimos Evangelatos; George E Fragoulis; Athanasios D Anastasilakis; Alexios Iliopoulos
Journal:  J Musculoskelet Neuronal Interact       Date:  2021-03-01       Impact factor: 2.041

2.  Transient regional osteoporosis of the hip with extensive bone marrow edema (BME): Dramatic improvement after three months of Alendronate therapy.

Authors:  Yasser Emad; Yasser Ragab; Mariam Ahmed Saad; Johannes J Rasker
Journal:  Radiol Case Rep       Date:  2021-07-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.